Paterna Biosciences Inc.

Paterna Biosciences Inc. is a US-based company specializing in innovative solutions for male infertility, utilizing cutting-edge in vitro spermatogenesis technology to enhance sperm production and viability for assisted reproductive technologies. Founded in 2020 and headquartered in Salt Lake City, US, Paterna Biosciences Inc. focuses on developing in vitro spermatogenesis (IVS) technology.

The company has engaged in one significant deal, raising USD 6. 000 mn in a Seed round led by Springtide Ventures on October 28, 2024, which also included investors such as Divergent Capital, Freya Ventures, Seaside Ventures, and Utah Innovation Fund. The company was created to address the challenges of male infertility through scientific advancements in reproductive health. Paterna Biosciences specializes in pioneering solutions for male infertility through its core product offering of in vitro spermatogenesis (IVS) technology.

This innovative service addresses the significant challenge of male infertility, impacting countless couples attempting to conceive. By leveraging adult testicular stem cells, Paterna facilitates the production of healthy, optimized sperm, enhancing the quality and viability used in assisted reproductive technologies such as in vitro fertilization (IVF). The company primarily targets fertility clinics and healthcare providers to provide new treatment options for couples facing infertility issues. Paterna Biosciences generates revenue through partnerships and collaborations with fertility clinics and healthcare institutions that utilize its in vitro spermatogenesis technology.

The transactional structure typically involves service agreements where clinics integrate Paterna’s technology into their IVF procedures, allowing them to offer enhanced fertility solutions to their clients. This B2B model supports clinics in improving their IVF success rates, attracting more couples seeking reproductive assistance. The company’s flagship service is based on proprietary advancements in sperm stem cell technology, ensuring a competitive stance in the fertility solutions landscape. In October 2024, Paterna Biosciences Inc.

raised USD 6. 000 mn in Seed funding to expand its team, build infrastructure, and advance its IVS technology through preclinical development. The company plans to launch new products designed to improve male fertility treatments and aims to penetrate additional global markets, with specific focus on regions with growing demand for advanced reproductive health services. The recent funding will facilitate these expansions and support the ongoing development of innovative solutions in the field.